NIU Technologies Reports Q4 and FY2019 Financial Results: Revenues Up 40.5%

NIU Technologies (“NIU”; NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, announced financial results for the fourth quarter and full year ended December 31st, 2019.

Revenues and Net Income Grow Four Consecutive Quarters

Driven by the increased sales volume up 13.5% and increased revenues per e-scooter up 10.5%, revenues for the fourth quarter of 2019 reached RMB 536.1 million, an increase of 25.4% YoY. The fourth quarter 2019 was profitable with net income of RMB 60.7 million, compared with a net loss of RMB 32 million in the fourth quarter 2018. The company has now been profitable for four consecutive quarters.

For the full 2019 financial year, NIU’s net revenues were RMB 2.0763 billion, an increase of 40.5%, which was mainly driven by increases in e-scooter sales volume of 24.1% and net revenues per e-scooter of 13.2%. China represented 85.1% of net revenues from e-scooter sales, and overseas markets represented 14.9%. The full year’s net income was RMB 190.1 million, which is an increase of RMB 539.1 million from a net loss of RMB 349 million in 2018.

Continued Growth Across Overseas Market

As a leading provider of smart urban mobility solutions, NIU has been improving its products and building further growth in overseas markets.

In December 2019, NIU’s new manufacturing facility in Changzhou commenced operation. The new facility covers about 75 acres and has a designed capacity of 700,000 units per annum. In the fourth quarter of 2019, NIU’s international sales network expanded to 29 distributors covering 38 countries.

In addition, in January 2020, NIU launched two new products, the RQi-GT and TQi-GT. The RQi-GT is NIU’s first urban performance electric motorcycle and the TQi-GT is NIU’s first electric three-wheeler vehicle.

So far, global users of NIU have exceeded 1 million with a cumulative rider distance of 4.5 billion kilometers. NIU has also contributed to cumulative carbon emission reductions of 1.14 million tons, which is the equivalent to planting 57 million Saxaul. It demonstrates NIU’s commitment to corporate social responsibility and “providing more convenient and environmentally friendly transformative urban travel transportation for global users”.

The company has been monitoring the Coronavirus pandemic very closely. Since the restart of operations, NIU has implemented safety measures such as daily disinfection of retail locations, factories and corporate offices to ensure the well-being of our customers and employees. The company is also aware of the potential economic damage towards the global economy and the confidence of consumers. NIU has implemented new campaigns to expand its online sales by working with online retail partners in both China and overseas market.

Dr. Yan Li, CEO of NIU said “we delivered solid revenue growth and improved gross margin. The Company continued to operate profitably. We are very excited about the growth perspective of our business and are committed to expanding our production capacity to meet the increasing demand. We look forward to sustaining the growth of our business.”

Agilex Biolabs Announces 30% Labs Expansion and Offers Virtual Lab Tours During COVID-19 Outbreak

Adelaide, AUS – (ACN Newswire) – Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has expanded its lab facilities by more than 30% to accommodate demand, mainly from US and APAC-based biotech companies.

As the only FDA-inspected lab of its type in the region, Agilex is located in Adelaide, South Australia, in a science and biotech specialist hub.

The company specialises in bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS and Immunoassay (MesoScale, Gyrolab).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:

– Immunophenotyping

– Receptor occupancy

– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine / biomarker profiling

– PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs CEO Jason Valentine said they will now be offering virtual tours of the lab for customers who have travel restrictions during the current Covid-19 outbreak.

CEO Jason Valentine said:

“Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma / biotechs from US, Europe and APAC.

“By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.

“Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.”

Learn more:

– Watch the Agilex Biolabs video: https://youtu.be/3lyodiqqM_k

– Download the New Services data sheet: https://tinyurl.com/AgilexBiolabs

About Agilex Biolabs

Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980’s, and has now grown into a global business for early phase clinical trials. In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world. Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA. Call +61 8 8302 8777 or +1 800 247 1909 or visit https://www.agilexbiolabs.com/.

Media Contact:

Team@DMGPR.Com

David James

AU: +61 2 8218 2144

USA: +1 415 951 3228

Asia: +65 3159 3427

Hua Medicine Announces 2019 Annual Results

Pivotal Phase III Trial Achieved Clinical Efficacy Endpoint at 24 Weeks
Dorzagliatin-Driven Portfolio Expands

Hua Medicine (the “Company”, Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. For the year ended December 31, 2019, the Company incurred approximately RMB468.5 million in total expenses, of which approximately RMB 321.9 million was research and development expenses. As of December 31, 2019, the Company’s cash position was approximately RMB 1,105.6 million.

Hua Medicine will continue to execute on its strategic goal of becoming a global diabetes care and management company, and is devoted to the development, registration and launch of dorzagliatin (HMS5552) in China and around the world. Hua Medicine achieved many milestones in 2019. The core scientific concept for dorzagliatin as a first-in-class drug was further validated, and the dorzagliatin-driven portfolio of diabetes therapies reflected in our pipeline continued to expand and advance. The Phase III monotherapy trial (HMM0301) for dorzagliatin (HMS5552) achieved its primary efficacy endpoint. The study results indicated that dorzagliatin was well tolerated during the 24-week study period, exhibited very low incidences of hypoglycemia and had a good safety profile. Meanwhile, two Phase I clinical trials with dorzagliatin (HMM0110 and HMM0111) also demonstrated satisfactory results. The results of HMM0110 demonstrated that dorzagliatin has the potential to be used in Type 2 diabetes (T2D) patients with moderate, severe and end stage chronic kidney disease (i.e., stages 3-5 of CKD); several top-selling oral anti-diabetes drugs must undergo dose adjustment (e.g., metformin and sitagliptin) when used for such T2D patients, or simply can’t be used at all for such patients (e.g., select SGLT-2 inhibitors). The results of HMM0111 confirmed the clinical advantages and potential synergies of dorzagliatin in combination with sitagliptin (a DPP-4 inhibitor), one of the best-selling oral anti-diabetic drugs globally.

The diagnosis rate of Type 2 diabetes is relatively low in China. Accordingly, there is a huge population of non-diagnosed and drug-naive T2D patients in China, which provides a big market opportunity for dorzagliatin. Current diabetes therapies still cannot effectively restore the healthy body’s ability to control blood glucose level autonomously, nor modify or stop the progression of diabetes into more advanced stages of the disease, leading to the development of diabetes-associated complications. In contrast, the results of pre-clinical and clinical studies (both completed and those currently under development) demonstrate that dorzagliatin has the potential to treat the underlying cause of Type 2 diabetes by fixing the impaired glucose sensor in all T2D patients and thereby restoring glucose homeostasis. Research data to date suggests that, as a cornerstone therapy, dorzagliatin possesses the potential of controlling the development of diabetes and preventing or delaying the occurrence of complications, either via monotherapy or through combination with currently available diabetes therapies.

“We will carry on implementing our developmental strategy, which consists of expanding in three dimensions: new products, global markets and new disease indications. By deploying dorzagliatin as a cornerstone therapy, we will establish an innovative, sharing and win-win scientific platform that focuses on the remodeling of glucose homeostasis, and eventually realize the personalized medicine of diabetes globally,” said Dr. Li Chen, Founder and Chief Executive Officer of Hua Medicine.

Clinical trial Highlights

– Achieved 24-week primary efficacy endpoint in a double blinded placebo controlled Phase III trial in drug naive Type 2 diabetes (T2D) patients in China (HMM0301), with very low hypoglycemia incidents and good safety profiles. As of March 2, 2020, the last patient out, 52-week (plus one-week follow-up) patient visit for HMM0301 was completed.
– Completed enrollment in a metformin add-on Phase III registration trial (HMM0302). As of February 16, 2020, the 24-week patient visit for HMM0302 was completed.
– Completed HMM0110, which demonstrated desirable pharmacokinetics profile in patients with end stage chronic kidney disease, indicating the potential use of dorzagliatin among T2D patients with moderate, severe and end stage chronic kidney disease (i.e. stages 3-5 of CKD).
– Completed HMM0111, which investigated the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of dorzagliatin either alone or in combination with sitagliptin (a DPP-4 inhibitor) in T2D patients, and demonstrated combination and synergy potential between the two drugs.
– Granted a formulation patent for dorzagliatin in China.
– Filed six patent applications covering the IPR of fixed dose combination of dorzagliatin with six classes of oral anti-diabetic drugs.
– Fully validated the cGMP (current Good Manufacturing Practice) commercial manufacturing processes for active pharmaceutical ingredient (API) and drug product to support the launch of dorzagliatin in China.

Operational highlights

– Initiated a formal collaboration relating to the central role of glucokinase in controlling glucose homeostasis with Dr. Franz Matschinsky,professor of Biochemistry and Biophysics, Institute for Diabetes, Obesity and Metabolism Perelman School of Medicine, Philadelphia and the recipient of the 1995 Banting Medal for Scientific Achievement and the 2020 Rolf Luft Award.
– Presented AI-based machine learning results at the American Diabetes Association’s 79th Scientific Sessions, providing a non-biased methodology to sub-classify T2D patients.
– Announced that global operation headquarters and research and development center were established in Shanghai’s ZhangJiang Science City.
– Former U.S. FDA Officer Dr. Fuxing Tang joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development.

Financial Highlights

– Cash position was approximately RMB1,105.6 million as of December 31, 2019.
– Loss before tax decreased by approximately RMB3,178.7 million or approximately 88.2% to approximately RMB425.3 million.

Future Pipeline Outlook

– The Company plans to announce top-line 52-week Phase III trial result for the monotherapy trial (HMM0301) by no later than third quarter 2020.
– The Company plans to announce top-line 24-week Phase III result for the combination with metformin trial (HMM0302) by no later than third quarter 2020, and top-line 52-week result by year end 2020.
– The Company plans to partner with either China-based or international pharmaceutical companies to make dorzagliatin and related products, as brand new therapies, available to patients, in both China and regions outside of China.
– HMM0109 is a Phase I trial studying the pharmacokinetics profile for hepatic impaired patients in China.
– HMM0112 is a dorzagliatin combination with empagliflozin (a SGLT-2 inhibitor) Phase I trial in T2D patients in the United States. The Company announced the first patient was dosed in April 2019 and expect to complete and announce results by first half 2020.
– In order to continue expansion of dorzagliatin’s indications for the treatment of T2D, the Company is investigating the combination of dorzagliatin with various approved classes of oral anti-diabetic medicines and expand the dorzagliatin-driven portfolio to address patients’ personal needs.

About Dorzagliatin
Dorzagliatin is a first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in people with type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of people with type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.

About Hua Medicine
Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of type 2 diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.

ASGE Releases Recommendations for Endoscopy Units in the Era of COVID-19

The American Society for Gastrointestinal Endoscopy (ASGE) has released an important article in its signature publication, the Gastrointestinal Endoscopy (GIE) journal. The article, titled “Coronavirus (COVID-19) Outbreak: What the Department of Endoscopy Should Know”, is written by ASGE member, Dr Alessandro Repici and his colleagues who have first-hand experience and are still in the middle of the COVID-19 crisis in Italy.

Endoscopy is a place where patients and physicians have very close distance and physicians are exposed to splashes, mucus or saliva during procedures especially upper gastrointestinal (GI) endoscopy. Moreover oral-fecal transmission has been postulated as a potential route for COVID-19 transmission. Endoscopy is also a place with significant concentration of people (staff, patients, caregivers, relatives, etc.) This is why establishing detailed and strict rules is of paramount importance to protect both personnel and patients.

Even though health care personnel working in endoscopy units are not directly involved in the diagnostic and therapeutic evaluation of COVID-19 positive patients, endoscopy should still be regarded as a risky procedure. This risk of exposure and subsequent infection of endoscopy personnel is, in fact, substantial in cases of patients with respiratory disease that can be spread via an airborne route.

The risk of exposure of endoscopy personnel is also not limited to upper endoscopy procedures, considering the recent detection of SARS-CoV in biopsy specimens and stools, suggesting a possible fecal-oral transmission. This could be even more relevant given that the virus transmission can occur during the incubation period in asymptomatic patients.

Establishing infection prevention measures and guidelines within an endoscopy department is essential for creating a high-quality and extremely safe environment to protect both patients and personnel. In this new era of the COVID-19 outbreak, it is imperative that these measures be implemented and maintained to avoid further spread of the disease.

“We recognize that ASGE members and their patients globally need to be diligent in maintaining individual health while minimizing disruption to day-to-day endoscopic practices and overall regional economies,” said John Vargo, MD, FASGE, President of ASGE. “It is a challenging time for the whole world, and endoscopists and physicians have the additional responsibility of protecting both patients and their own well-being.”

Read the GIE article. https://pr.report/IWK3r6dG

ASGE would like to express its appreciation to the authors for sharing their first-hand experience with other medical professionals around the world. They are currently in the middle of providing critical patient care at their medical institution, but felt it was important to also share their knowledge to minimize the global impact of this outbreak.

About the American Society for Gastrointestinal Endoscopy

Since its founding in 1941, the American Society for Gastrointestinal Endoscopy (ASGE) has been dedicated to advancing patient care and digestive health by promoting excellence and innovation in gastrointestinal endoscopy. ASGE, with more than 15,000 members worldwide, promotes the highest standards for endoscopic training and practice, fosters endoscopic research, recognizes distinguished contributions to endoscopy, and is the foremost resource for endoscopic education. Visit www.asge.org and www.screen4coloncancer.org for more information and to find a qualified doctor in your area.

For more information, contact:
Andrea Lee
Director of Marketing and Communications
American Society for Gastrointestinal Endoscopy
3300 Woodcreek Dr.
Downers Grove, IL 60515
USA
alee@asge.org
+1-630-5705603

SOURCE: American Society for Gastrointestinal Endoscopy

Aruba’s Global Cloud Data Center enhances international accessibility with Cogent PoP

LONDON – (ACN Newswire) – Aruba S.p.A., a leader in data centre and cloud enterprise services, has today announced the activation of a new presence point within its Global Cloud Data Center, based at its technology campus on the outskirts of Milan, provided by leading global internet service provider Cogent.

The point of presence will allow Aruba customers to benefit from Cogent’s extensive international network that extends across North America, Europe and Asia through more than 92,000km of intercity fibre and over 56,000km of metro fibre. This network provides services to over 204 markets and connects 6,840 additional networks.

The presence of an operator of this calibre – in addition to the others already partnered with Aruba – increases the range of carriers available within the Global Cloud Data Center. This gives customers access to a broader range of choices. The Global Cloud Data Center, like all Aruba data centres, is carrier-neutral and hosts numerous telecommunications operators with which customers can independently manage their relationships. Cogent now represents a new tier 1 option, joining TIM, Fastweb, Wind-Tre, Retelit, Irideos, Planetel and Vodafone.

The offer of multiple connections, together with the perfect mix of Italian and international operators, allows Aruba to guarantee the highest standards in terms of performance and redundancy.

Lorenzo Giuntini, CTO of Aruba commented: “This partnership adds great value to our offering. An operator like Cogent, a tier one service provider of international calibre, gives the Global Cloud Data Center appeal on a global scale and offers numerous benefits to customers thanks to the quality of the internet transit.”

Peter Menig, Sales Director of Cogent commented: “As the world becomes increasingly interconnected, carrier-neutral connectivity options like the one provided by the Global Cloud Data Center become more important. Cogent is pleased to have the opportunity to deliver high-quality IP transit services to Aruba data centre customers.”

Last year, Aruba announced the activation of a Point of Presence in the Milan Internet eXchange (MIX) – among the first in Europe and the largest Italian Internet eXchange in terms of vehicular traffic – directly accessible from the Global Cloud Data Center. The agreement provided the addition of new interconnections thanks to the use of a double fibre route to connect the equipment to Milan, thereby facilitating traffic exchange with numerous other national and international carriers.

This new activation marks the next step in the expansion of the Aruba Data Center network, which already has two new Data Centers arriving within the Global Cloud Data Center technological campus area. This growth will enable Aruba to provide the highest quality of service to all its customers, whether they are national or international.

For more information http://aru.ba/dcconnectivity

Aruba S.p.A.

Aruba S.p.A., founded in 1994, is the leading company in Italy for data centers, web hosting, email, certified email (PEC) and domain registration services. Aruba is also active in key European markets including France, the UK and Germany, and is the leader in the Czech Republic and Slovakia, with an established presence in Poland and Hungary. The company has a huge amount of experience in the management of data centers, with a European network capable of hosting over 200,000 servers.

Aruba manages 2.7 million domains, 8.6 million email accounts, 6.7 million certified email (PEC) accounts, 130,000 physical and virtual servers and a total of around 5.4 million customers. The company provides hosting services, public and private cloud services, housing and colocation services, dedicated servers, digital signature services, digital preservation, e-billing, certified email, SSL certificates and smart-cards.

Thanks to Aruba Business, founded in 2015, it offers all the services to a vast network of IT partners, and with Pratiche.it brand, the company provides document delivery and recovery services throughout Italy. In the same year, the Aruba.it Racing, Official Ducati Team in the World Superbike World Championship was born.

Since 2016 it has been the Official Registry for the prestigious “.cloud” extension. For over 10 years, Aruba Enterprise has been offering Cloud, Data Center and Trust Service solutions to businesses and public authorities, designing, implementing and managing highly customized IT solutions. For further information: https://www.aruba.it

Red Lorry Yellow Lorry

Philip Iacob

Senior Account executive

Email: aruba@rlyl.com

1929 Mask launches Antimicrobial Masks to counter Coronavirus

SINGAPORE – (ACN Newswire) – Keenon Lee, founder of Singapore-based 1929 Mask, has announced the launch of 1929 Antimicrobial Face Masks, easing pressure on the global supply of masks created by the spread of Coronavirus. With an increasing number of individuals affected by the virus, the product launch has arrived at the right time.

1929 Mask produces masks that are water repellent, antimicrobial and reusable with technology that eliminates bacteria and fungus, and allow for odour control, freshness and hygiene. The masks are non-toxic and eco-friendly with a high degree of efficacy and durability, resistant for more than 100 washes with textiles.

The 1929 Mask comprises three layers: the outermost layer is water repellent, the center layer is antimicrobial, and the innermost layer is moisture wicking to maintain user comfortable. Each layer in the mask has undergone rigorous, individual testing. All masks are certified safe and effective, using active ingredients approved by the FDA, EPA and WHO.

“The greatest way to prevent catching coronavirus, as well using a 1929 Branded Mask, is to delay any trips to places with known outbreaks,” says Lee. “You can also wash with your soap; avoid touching the eyes, nose and mouth with unwashed hands, and avoid close contact with those who are sick.”

It is common in some countries to observe individuals donning masks in public to protect against pathogens, however those masks help little with a virus. “Those masks are not designed to keep out viral particles and they’re not as fitted around the nose and cheeks,” he continued.

Most of the reusable masks are not tested, and are little more than common dust masks used in construction and other industries where airborne particulates are found. Some are using surgical masks, as they are sick with a cold and don’t wish to contaminate others. “If you’re sick, it’s best not to go to public places. That’s the time to stay at home,” he said.

Lee advised of five things people should remember:

1. Before putting on a mask, clean hands with alcohol-based hand rub or soap and water.

2. Be sure to cover your mouth and nose with a mask.

3. Avoid touching the mask while using it; if you do, clean your hands.

4. Replace the mask with a new one as soon as it is damp, and do not reuse single-use masks. Brand 1929 Microbial Masks are reusable.

5. To remove the mask: remove it from behind (do not touch the front of mask); discard in a closed bin; clean hands with alcohol-based hand rub or soap and water.

1929 Mask Pt Ltd is dedicated to creating innovative, efficient and eco-friendly mask solutions to reduce stress on the supply of face masks in the healthcare system. For more information, visit the company’s website at https://1929mask.com, or contact Keenon at info@1929mask.com.

Further Analyzing Coronavirus Cases against Average Temperatures

TOKYO – (ACN Newswire) – A group of consultants at Azabu Insights Inc., a strategic consulting company in Azabu Juban Tokyo, have been analyzing data to understand the correlation between air temperature and spread of the coronavirus (Covid-19).

Last week we made the case that coronavirus seems to be spreading more in colder countries than in warmer countries and that there might be some respite for the Northern Hemisphere countries if we can make it to the warmer part of spring without numbers jumping up too aggressively.

This weekend we analyzed more data, more carefully, in two geographic models. First, we analyzed the number of cases in each of Japan’s forty-seven prefectures (akin to States in the US). Second, we looked at countries and their mean monthly temperatures. Lastly, we looked at velocity of growth.

Japan Cases Overrepresented in Colder Prefectures

Japan is interesting to look at. Despite having only 126 million people living in 377,900 square kilometers (about the size of Montana), it spreads North and South from latitudes in line with Maine and Florida. The temperature dispersion is, not surprisingly, significant. Okinawa, which has about the same latitude as Miami, Florida, had an average February temperature of 16 degrees celsius (61 fahrenheit), whereas Sapporo, which has a latitude similar to Portland, Maine, had an average temperature of minus 4.2 degree celsius (24.4 fahrenheit).

In the below chart we included all of the prefectures of Japan, sorting them with the most Coronavirus infections at the top and going all the way down to zero infections at the bottom. An analysis of the prefectures below shows a number of interesting insights. First off we see that all of the areas with significant infection counts are considered either cold or very cold in February. Okinawa, as mentioned, is a warmer prefecture and had only three cases despite being one of the areas with many Chinese tourists.

We color coded the average temperatures across prefectures for every month of the year (the average of low and high temperature) into five categories, as below. The next insight is that most of the prefectures will need to wait until April or May to reach the February temperatures of Okinawa; temperatures will remain high through October.

1. Outbreak in Japanese Prefectures, Mapped Against Average Temperature Celsius
http://www.acnnewswire.com/topimg/Low_Azabu20200310-1.jpg

International Outbreak vs Temperature: 94-98% of Cases in Cold Regions

We next analyzed the international outbreak vs. temperature. Again, some interesting insights come through. First off we noticed that fourteen of the top fifteen countries were all “very cold” or “cold” in February. One country, Spain, was classified as “middle” temperature; it has the seventh most cases (as of March 8, 2020). Spain had an average temperature of eight degrees in February which, while certainly not hot, was somewhat warmer than the average of three degrees across the top fifteen countries.

Further, we noted that there are currently fifty-one countries with at least ten cases. Of the total number of cases 22,967 or roughly 93 percent were in “cold” or “very cold” regions, excluding China. This number would be 103,655 or roughly 98 percent of cases including China. There were 880 cases in warm and middle regions and 753 in hot regions.

2. Total Infection Cases, Countries with greater than ten Covid-19 cases (excl. China)
http://www.acnnewswire.com/topimg/Low_Azabu20200310-2.jpg

3. Total Infection Cases, Countries with greater than ten Covid-19 cases (incl. China)
http://www.acnnewswire.com/topimg/Low_Azabu20200310-3.jpg

Looking at it on a country basis, just over half of the top fifty-one countries were in cold or very cold regions. Again, we caution not to read too much into this, since the aggregate numbers are skewed so high to cold regions. Cases do exist in many warm countries, but there are less of them and they seem to be spreading less quickly.

Further drilling down we see that Singapore and Hong Kong had 138 and 108 cases respectively, a large number amongst hot countries. These countries have a huge number of Chinese visitors but had surprisingly low outbreak rates. They are also interesting because they are very much “indoor” cities, where many people spend their time in large air conditioned buildings and indoor pedestrian walkways and shopping malls. From our discussions with people in Hong Kong and Singapore and from media reports we know that both cities have worked very aggressively to combat the outbreak. It is unclear whether their success is due to their hard work in combating it or due the temperature support or a combination.

4. Percentage of Top 51 Countries with Outbreaks
http://www.acnnewswire.com/topimg/Low_Azabu20200310-4.jpg

Upcoming Winter in the Southern Hemisphere

One concern that we identified was, as the northern hemisphere warms in May and June, that the Southern Hemisphere would be entering their colder winter months and, as such, potentially see an increase in outbreaks and the speed of spread of coronavirus.

On closer examination however we see that Southern Hemisphere winters are milder than many places in the Northern Hemisphere. For example, Hobart is Australia’s coldest city and has an average temperature of 8.2 degrees celsius in July which would be classified as “middle” temperature. Similarly Bloemfontein in South Africa (7.2 degrees) and Santiago in Chile (8.2 degrees) are mild. Note, some smaller cities in the Southern and mountainous areas of South America, have colder temperatures, such as Punta Arenas in Chile with a July temperature of 1.5 degrees.

Overall we are hopeful that the milder Southern Hemisphere winters will result in slower spread and less outbreaks through the middle of 2020.

Long Summers in Many Countries

We see that many countries are clustered closer to the equator. This includes South East Asia, much of South Asia, the Middle East, the majority of Africa and much of South and Central america. Of the 51 countries where we have seen at least 10 cases, 23 of them have 6 months or more classified as “hot”, with 13 of these countries “hot” all year round. Following the assertion that coronavirus spread is slower in hotter environments, this high number of hot months bodes well for a slowing of the spread of the virus over the ensuing months.

Conversely, we hold concerns for countries with very short summer seasons, particularly in Northern Europe. Global financial center London in the UK for example, only has 2 hot months for the year as does Amsterdam in the Netherlands. While Russia may see less inflow and outflow of people than London it is an outlier with every month of the year either cold or very cold. The potential for outbreaks and continued spread in these countries remains and should be continue to be monitored closely.

Velocity of Spread

A final insight from the data comes from an analysis of the velocity of growth in warm versus cold regions. We found, when analyzing the ten regions we had previously looked at, that the rate of growth of the cases between March 3 and March 8th was faster in the colder regions (average growth of 185%) than in the warmer regions (average growth of 50%). This is to say, while Singapore had a fair number of cases early, their growth from March 3rd to 8th has been slow (only 25%). Cases for countries, such as Washington State (467%) France (397%), Iran (288%), and Italy (189%) all grew very quickly, during the same period. Amongst warm regions we had reviewed, one concern was Malaysia, which had cases jump 158%.

5. Increase in cases by region
http://www.acnnewswire.com/topimg/Low_Azabu20200310-5.jpg

Within Japan we also looked at velocity and found a major jump in Japan’s second largest city, Osaka. Osaka is another cold populous city (8.8 million people) with lots of train travel and public gatherings. Numbers jumped to fifty-five cases from eight cases, a growth of 412%. Local media is reporting that this is connected to a cluster around live music events. Japan has also faced a shortage of masks in the past week, with many convenience stores receiving shipments of only two or three masks at a time. Rough counts on the street seem to show less people wearing masks than a week ago, when they were more available.

Osaka is Japan’s second largest city and is home to a number of very famous listed companies, which may be further affected by the outbreak. These include: Takashimaya (TSE1: 8233), Capcom (TSE1: 9697), Teijin (TSE1: 3401), Panasonic (TSE1: 6752), Daikin Industries (TSE1: 6367).

Refer to the table below to view the cases and average temperatures in the fifty-one countries with ten or more cases. Looking at the pattern of temperature rise across the most affected countries, we see that most will need to wait at least until April or May (and some as late as June) to be classified as “warm” or “hot”. There is then a respite until about October when temperatures will drop and be very supportive of the virus spread again.

6. Case Counts and Monthly Temperatures for 51 Countries with greater than ten Covid-19 cases
http://www.acnnewswire.com/topimg/Low_Azabu20200310-6.jpg

Conclusions

As with our previous article, we conclude that Covid-19 can spread in warm regions but seems to spread much more quickly in colder regions. We hope that countries and regions around the world will aggressively work to keep the virus at bay until the summer months and hope that the warm temperatures will support further containment.

Comments on our analysis are welcome at the email below.

About Azabu Insights

Azabu Insights is a boutique strategic consulting company based in Azabu Juban, Tokyo, Japan. Our teams work collaboratively with clients to build strategies that lead to positive change. Our multilingual team members have top tier academic backgrounds and deep industry experience that we leverage to provide first class, fully engaged, strategic consulting. Core specializations include life sciences, finance, electronics, automotive, aerospace and other industries. For more information contact: info@azabuinsights.com.

Yidan Prize Conference Series: Europe 2020 Held at Cambridge, with a Focus on Important Global Education Issues

Cooperation Between the Two Organizations Deepened, Advance Global Education Together

Yidan Prize Conference Series: Europe 2020 hosted at Jesus College, Cambridge
Dr Charles Chen Yidan at the Conference
Professor Usha Goswami, Yidan Prize for Education Research Laureate 2019

Yidan Prize Conference Series: Europe 2020 was held at Jesus College, the University of Cambridge. This year’s conference focused on two themes: education and international development; wellbeing and education.

This year’s Yidan Prize Conference Series: Europe 2020 honored the achievements of the Yidan Prize for Education Research Laureate 2019, Professor Usha Goswami, and also honored the work of the Yidan Prize for Education Development Laureate 2019, Sir Fazle Hasan Abed KCMG. He died in late December 2019. Sir Fazle was the Founder of BRAC, one of the world’s largest non-profit development organizations, which currently operates across 11 countries in Africa and Asia and has set up hundreds of early childhood development centers, where close to 40,000 children are presently enrolled.

“The 2019 Laureates represent two very different approaches to ensuring that our children go on to lead happy, productive lives, but they also intersect. Both point to the need to achieve a better, deeper understanding of children’s needs. Through their work, we now see promising ways to help millions of lives around the world. With technology, and active participation of our partners on this global platform, we can inspire hope for our future generations.” Dr Charles Chen Yidan, the founder of the Yidan Prize said at the conference.

The University of Cambridge’s Vice-Chancellor, Professor Stephen Toope said that the university had a ‘critical’ role to play in addressing the challenges of mental health, and it goes to the heart of what we stand for as a center for research and practice in education.

Professor Pauline Rose, Director of Research for Equitable Access and Learning Center, the University of Cambridge, said that inspired by the achievements of Sir Fazle, this year’s conference discussed what works in education for the most marginalized communities.

“BRAC since the 1980s has been a world-leader in this area. BRAC’s impact seems to stem from the fact that they gather evidence about their effectiveness and adapt their programmes accordingly, which helps to make their work adaptable and replicable in other countries. At the REAL Centre at the Faculty of Education, we have carried out assessments that suggest that similar reasons lie behind the success of another organization, CAMFED, in supporting the education of marginalized girls in Tanzania,” she said.

BRAC IED’s Executive Director Erum Mariam attended the conference. She said Sir Fazle dedicated his life to serve the needs of people living in poverty all around the world. Among his many contributions, he is best known for making girls’ education a priority in Bangladesh with women as the drivers of change.

“Sir Fazle scaled a unique non-formal primary education model in every district of Bangladesh maintaining a strict policy of opening a one room school only if 70 percent of the students are girls. Started in 1985 BRAC’s s non-formal schools have had six million graduates who would have otherwise been left behind,” Erum Mariam said.

Professor Anna Vignoles from Faculty of Education, University of Cambridge, hosted a panel discussion on children’s mental health. She found that there is a growing global awareness of the mental health needs of children, and a growing consensus that mental health is an important indicator of the success or otherwise of any society.

“Children in particular experience a range of problems and challenges, including poverty, abuse, bereavement etc. Evidence from the World Health Organisation survey suggests that around a third of all mental health problems are down to such childhood adversities. We need to be clear what the main factors causing any increase in young people’s mental health problems are, and the extent to which they really can be addressed by schools, rather than requiring a wider societal response. Second, we need to have far better evidence on what kinds of interventions are effective in a school setting, and reassure ourselves that schools are indeed the right institutions to be tackling the problem,” Anna Vignoles said.

“We look forward to finding many more innovative solutions through working closely with educators who share our passion and determination to build a more inclusive society for everyone. Together, we can transform great ideas into meaningful actions. It is on the notion of the need for closer collaborations and collective impact that we curate these debates to create a new philosophy for the future of education,” Dr Charles Chen Yidan said.

At Yidan Prize Conference 2020, Professor Toope announced officially that the University of Cambridge would be creating a new role – Professor of Psychology of Education and Learning Studies, which will be based in its Faculty of Education. The new post will strengthen existing research into how better to support young people’s well-being and mental health, in particular through the education system.

The first post-holder will be Professor Gordon Harold, currently at the University of Sussex, who has led several, field-changing studies into the relationship between domestic adversity and young people’s mental health, enabling schools and teachers to do more to support pupils with depression and anxiety.

The conference was broadcast live online to encourage educators from around the world to participate in discussions on important educational issues.

About the Yidan Prize

Founded in 2016 by Dr Charles Chen Yidan, a core founder of Tencent, the Yidan Prize has a mission of creating a better world through education. It consists of two awards, the Yidan Prize for Education Research and the Yidan Prize for Education Development. Yidan Prize Laureates each receives a gold medal and a total sum of HK$30 million (around US$3.9 million), half of which is a cash prize while the other half is a project fund. To ensure transparency and sustainability, the prize is managed by the Yidan Prize Foundation and governed by an independent trust with an endowment of HK$2.5 billion (around US$323 million). Through a series of initiatives, the prize aims to establish a platform for the global community to engage in conversation around education and to play a role in education philanthropy.

Big Data World x Artificial Intelligence – 4th edition at Marina Bay Sands

SINGAPORE, Mar 10, 2020 – (ACN Newswire) – After 3 successful years, Big Data World, Singapore will realign its focus to incorporate “artificial intelligence”, and will be renamed Big Data & AI World in its 4th edition at Marina Bay Sands Expo and Convention Centre on 14th – 15th October 2020.

Aligned with the direction of the Singapore government to develop Singapore into an AI Hub, and with the roll-out of Singapore’s National Artificial Intelligence Strategy, Big Data & AI World brings artificial intelligence to the forefront of this exhibition. This includes the development of a dedicated Artificial Intelligence Keynote Theatre featuring top AI experts in Asia who will share how companies can incorporate AI technologies for business success.

Over 5,000 industry professionals are expected to attend and explore offerings from over 90 global exhibitors including TIBCO, Altair, Denodo, H2O.ai, Keysight, Softserve, Teradata and more.

Dr Sean Lam, Head of Data Science with SingHealth Health Services Research Centre (HSRC), who spoke at the 2019 edition of Big Data World said, “It has been a great pleasure to witness the show evolve to meet industry needs. As we continuously leverage artificial intelligence and data science to deliver better healthcare outcomes, I’m excited to see how Big Data & AI World’s new focus on artificial intelligence will further add value to the healthcare industry in the region.”

Group Event Manager, Neil Halliday said: “It’s an exciting time for us. Plans have been in place to develop the artificial intelligence space after feedback from our attendees last year. We aim to satisfy the gap in the market for a dedicated artificial intelligence exhibition, and can’t wait to reveal the exciting developments that the event will bring this October!”

For details on Big Data & AI World, please visit www.bigdataworldasia.com

For details on the National Artificial Intelligence Strategy, visit www.smartnation.sg/why-Smart-Nation/NationalAIStrategy

For media enquiries, please contact Nic-cole Chia at n.chia@closerstillmedia.com.

About CloserStill Media

CloserStill Media specialises in international professional events chiefly in the technology markets, across five global territories. Its portfolio includes some of the UK’s fastest-growing and award-winning events including Cloud Expo Europe and Data Centre World. Having delivered unparalleled quality and relevant audiences for all its exhibitions, CloserStill has been repeatedly recognised as a leading innovator with its teams and international events winning multiple awards in Europe and Asia including Best Marketing Manager – four times in succession – Best Trade Exhibition, Best Launch Exhibition, and Rising Star – two years in succession – among others.

For more information, visit www.closerstillmedia.com.

New GeoMap Tools Get Patient Recruitment Back on Track During the COVID-19 Outbreak

Award-winning global leader in digital patient recruitment GeoMap Clinical by TrialWire announced today new tools added to the GeoMap geo-targeting Platform that can restore and boost patient recruitment numbers at a time when people are avoiding clinic appointments for fear of COVID-19.

The GeoMap Platform is currently recruiting for clinical trials in North America, Latin America, Australia, New Zealand, Asia and the EU.

The company said:

“Most studies require at least 1 clinic visit for check-ups, monitoring and tests, but many sponsors, investigators and study coordinators are finding that potential patients are staying away because of fear of contracting the virus in a clinic.

Increasingly people are also not traveling unless they really need to – especially people with underlying conditions, which is much of the potential clinical trial patient community.”

The GeoMap Platform has introduced a range of new tools to recruit patients as part of the GeoMap process which includes online screening using the Proprietary AI Patient Screener Funnel of more than 300+ possible questions, and direct secure encrypted contact with the study coordinator for a phone call.

The Platform is the fastest most accurate targeting tool available that doesn’t require IRB/EC approval and can start recruiting in under 24 hours.

The Platform had strict verification and email encryption so PHI is managed in accordance with state and country regulatory guidelines.

For a full briefing on the new recruitment support tools on the GeoMap Clinical Platform, please click here:
https://www.geomap-clinicaltrialfinder.com/patient-recruitment-covid-19/

About GeoMap Clinical – https://www.trial-wire.com/

The GeoMap Clinical Platform is the world’s most advanced geo-location/targeting and AI platform powered by specialist algorithms that find and screen the right people living or working near sites.

The Platform is a sophisticated location and health profile search service that sends only highly eligible people to their nearest site.

It has been designed to end pain points across the clinical trials sector saving time and money at every stage, while ensuring patient privacy and regulatory compliance.

The GeoMap Clinical Platform is not a database builder. Patient ID is redacted instantly and the focus is instead on finding only motivated patients to support enrollment and retention.

For a briefing, please see www.geomap-clinicaltrialfinder.com/patient-recruitment-covid-19/

Media Contact:
Chris Thompson
team@dmgpr.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427